Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutation

被引：10

作者：

Coude, Marie-Magdelaine ^{[1
]}

Luycx, Odile ^{[2
]}

Cariou, Marie-Estelle ^{[3
]}

Maarek, Odile ^{[1
]}

Dombret, Herve ^{[4
,5
]}

Cayuela, Jean-Michel ^{[1
]}

Rea, Delphine ^{[4
,5
]}

机构：

[1] Hop St Louis, AP HP, Lab Cent Hematol, Paris, France

[2] Ctr Hosp Bretagne Sud, Med Serv, Lorient, France

[3] Ctr Hosp Bretagne Sud, Hematol Lab, Lorient, France

[4] Hop St Louis, Serv Malad Sang, Paris, France

[5] Hop St Louis, EA3518, Paris, France

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2012年 / 157卷 / 03期

关键词：

CML; BCR-ABL1; leukaemia therapy; mutations; HOMOHARRINGTONINE; INHIBITOR;

D O I：

10.1111/j.1365-2141.2011.09016.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：407 / 410

页数：4

共 9 条

[1]

[Anonymous], BLOOD

[2] Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification [J].

Gorre, ME ;

Mohammed, M ;

Ellwood, K ;

Hsu, N ;

Paquette, R ;

Rao, PN ;

Sawyers, CL .

SCIENCE, 2001, 293 (5531) :876-880

[3]

Lavallade H., 2007, BLOOD, V110, P2779

[4] BCR-ABLT315I transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine:: a new therapeutic challenge? [J].

Legros, L. ;

Hayette, S. ;

Nicolini, F. E. ;

Raynaud, S. ;

Chabane, K. ;

Magaud, J-P ;

Cassuto, J-P ;

Michallet, M. .

LEUKEMIA, 2007, 21 (10) :2204-2206

[5] Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib [J].

Marin, D ;

Kaeda, JS ;

Andreasson, C ;

Saunders, SM ;

Bua, M ;

Olavarria, E ;

Goldman, JM ;

Apperley, JF .

CANCER, 2005, 103 (09) :1850-1855

[6]

Nanda N., 2011, HAEMATOLOGICA, V96, pS2

[7] The Durable Clearance of the T315I BCR-ABL Mutated Clone in Chronic Phase Chronic Myelogenous Leukemia Patients on Omacetaxine Allows Tyrosine Kinase Inhibitor Rechallenge [J].

Nicolini, Franck E. ;

Chomel, Jean-Claude ;

Roy, Lydia ;

Legros, Laurence ;

Chabane, Kaddour ;

Ducastelle, Sophie ;

Nicolas-Virelizier, Emmanuelle ;

Michallet, Mauricette ;

Tigaud, Isabelle ;

Magaud, Jean-Pierre ;

Turhan, Ali ;

Guilhot, Francois ;

Hayette, Sandrine .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (05) :394-399

[8] Overriding imatinib resistance with a novel ABL kinase inhibitor [J].

Shah, NP ;

Tran, C ;

Lee, FY ;

Chen, P ;

Norris, D ;

Sawyers, CL .

SCIENCE, 2004, 305 (5682) :399-401

[9] Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl [J].

Weisberg, E ;

Manley, PW ;

Breitenstein, W ;

Brüggen, J ;

Cowan-Jacob, SW ;

Ray, A ;

Huntly, B ;

Fabbro, D ;

Fendrich, G ;

Hall-Meyers, E ;

Kung, AL ;

Mestan, J ;

Daley, GQ ;

Callahan, L ;

Catley, L ;

Cavazza, C ;

Mohammed, A ;

Neuberg, D ;

Wright, RD ;

Gilliland, DG ;

Griffin, JD .

CANCER CELL, 2005, 7 (02) :129-141

← 1 →